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Sunday, May 20, 2012  
 
 
15:30 – 18:00 Conference check-in  
 
18:00 – 18:30 Welcoming Remarks and Opening of the Conference 
 
                                                    Conference Chairs Introduction 
                                                    Celebrating 50 years of ECI Conferences - John Aunins 
 
18:30 – 19:30 Keynote 
 Malaria Vaccines as a model of vaccine development 
 David Kaslow, PATH, Malaria Vaccine Initiative, USA 
 
19:30 – 20:15 Welcome Reception with Folk Dancing 
 






• Technical Sessions will be held in Sala Grande Real. 
 
• Poster Sessions will be held in Grande Real Foyer. 
 
• Most meals will be in the Restaurante do Real.  Changes will be announced.  
 
• The conference banquet on Thursday will be held in the Restaurante Santa Eulalia. 
 
• Audiotaping, videotaping and photography of presentations are prohibited. 
 
• Speakers – Please leave at least 5 minutes for questions and discussion. 
 
• Please do not smoke at any conference functions. 
 
• Turn your cellular telephones to vibrate or off during technical sessions. 
 
• After the conference, ECI will send an updated participant list to all participants.  Please check your 








Monday, May 21, 2012 
 
 
07:00 – 08:30 Breakfast 
 
08:30 – 11:00 Session I: Vaccine target identification and validation 
 Session Chairs:   
 George Siber, Genocea 
 David Weiner, University of Pennsylvania 
 
08:35 – 09:05 Comprehensive T-cell antigen discovery using a genomic approach  
  Jessica Flechtner, Genocea Biosciences, USA 
 
09:05 – 09:35 Rational design of a fully synthetic nanoparticle-based vaccine for smoking 
 cessation  
 Takashi Kei Kishimoto, Selecta Biosciences, USA 
  
09:35 – 10:05 Tolerogenic vaccination exploiting apoptotic mechanisms via erythrocyte-to-
 hepatic targeting  
 Jeffrey A. Hubbell, Ecole Polytechnique Federale de Lausanne (EPFL), Switzerland 
 
10:05 – 10:30 Development of a vaccine against clostridium difficile infection:  Design, 
 purification and biological activities of recombinant toxin antigen fragments 
 Jerzy Karczewski, Merck, USA 
 
10.30 – 11:00                              Coffee break 
 
11:00 – 11:30 Molecular deconvolution of the monoclonal antibodies that comprise the 
 serum response to vaccination 
 George Georgiou, University of Texas, USA  
 
11:30 – 13:10 Session II: Technology challenges in developing world market  (Part 1) 
 Session Chairs:  
 Leda Castilho, Federal University of Rio de Janeiro 
 Paula Alves, IBET 
 
  Sponsored by ATMI Life Sciences 
 
11:30 – 12:00 Instituto Butantan - 111 years producing immunobiologicals: New challenges 
 Jorge Kalil, Instituto Butantan, Brazil  
 
12:00 – 12:20 PATH vaccine global development program 
 George A. Robertson, PATH, USA 
 
12:20 – 12:50 Recombinant VLP based human vaccines for emerging markets  
 Qinjian Zhao, Xiamen University, China  
 
12:50 – 13:10 Establishing human vaccine manufacturing in Southern Africa 
 Morena Makhoana, The Biovac Institute, South Africa  
 
13:10 – 14:00 Lunch 
 
 
Monday, May 21, 2012 (continued) 
 
 
14:00 – 15:30 Session III:  Late stage and recently launched vaccines  
 Session Chairs:   
 Nathalie Garcon, GlaxoSmithKline 
 Kathrin Jansen, Pfizer 
 
 Sponsored by GE Healthcare Life Sciences  
  
14:00 – 14:30 Development of Pfizer bivalent RLP2086 vaccine for prevention of invasive 
 disease caused by Neisseria Meningitidis Serogroup B 
 Joe Eiden, Pfizer, USA 
 
14:30 – 15:00 Recombinant influenza vaccine 
 Manon Cox, Protein Sciences, USA  
 
15:00 – 15:30 Process understanding approach for a late-stage recombinant protein 
 vaccine produced in Saccharomyces Cerevisiae  
 José Manuel Otero, Merck, USA 
 
15:30 – 17:00 ad hoc sessions, free time 
 
17:00 – 19:00 Session II: Technology challenges in developing world market (Part 2) 
 
17:00 – 17:30                              Challenges in development of an anti-idiotypic cancer vaccine  
                                                    Adolfo Castillo Vitlloch Center of Molecular Immunology, Cuba 
 
17:30 – 18:00 Expectation of China's contribution to world vaccine development and 
 supplies:  Status, strategy and international approach  
 Li Shi, Shanghai Zerun Biotechnology Ltd. Co., China  
 
18:00 – 18:20 Rabies virus-like particles expressed in HEK293 cells  
 Diego Fontana, Universidad Nacional del Litoral, Argentina 
 
18:20 – 18:40 The role of public-private partnerships in advancing vaccine 
 technologies and improving vaccine effectiveness and delivery for 
  developing countries  
 Ray Cummings, PATH, USA 
 
18:40 – 19:00 Challenges in clinical batches production of malaria vaccines  
 Nicolas Havelange, European Vaccine Initiative, Germany 
  
19:00 – 20:30 Dinner 
 




Tuesday, May 22, 2012 
 
 
07:00 – 08:30 Breakfast 
 
08:30 – 10:30  Session IV: Vaccine stability, characterization and delivery  
 Session Chairs:  
 Debbie Drane, CSL Limited 
 Robert Evans, Merck, USA 
  
08:30 – 08:50 Optimization of vaccine thermal stability through high-throughput 
 formulation - Development of a screening platform and application to measles 
 vaccine 
 Iain McFadyen, ex-Transform Pharmaceuticals, Inc., USA 
  
08:50 – 09:10 Nanopatches for targeted vaccine delivery to skin: Improving vaccines 
 Mark Kendall, AIBN, University of Queensland, Australia 
 
09:10 – 09:30 Formulation and stability studies for a Chikungunya virus-like particle (Chikv 
 VLP) based vaccine  
 Richard Schwartz, Vaccine Production Program Laboratory/VRC/NIAID, USA 
  
09:30 – 09:50 High throughput formulation design for a stable lyophilized virus-like 
 particle vaccine against Group A Streptococcus  
 Yap Pang Chuan, AIBN, University of Queensland, Australia 
 
09:50 – 10:10 Challenges in optimizing formulations for multi-antigen vaccines  
 Lakshmi Khandke, Pfizer, USA 
 
10:10 – 10:30 Stabilization technology for viral vaccines and adjuvanted vaccines  
 Stephen Ward, Stabilitech Ltd., UK 
 
10:30 – 11:00 Coffee break 
 
11:00 – 13:00 Session V: Veterinary vaccines  
 Session Chairs:   
 Robert Nordgren, Merial 
 Ian Tarpey, Merck 
 
11:00 – 11:30 A new successful vaccine against babesiosis:  Any use for malaria?   
 Theo Schetters, Merck, USA 
 
11:30 – 12:00 Leishmaniasis vaccine development:  Animals as models and patients 
 Steven Reed, IDRI 
 
12:00 – 12:30 Rift valley fever:  Next generation vaccines for an old foe 
 Brian Bird, CDC, USA 
 
12:30 – 12:50 Functional genomics as a tool to define a molecular signature of effective 
 vaccination against foot and mouth disease virus  
 Jose A. Chabalgoity, Departamento de Desarrollo Biotecnologico, Facultad de 
 Medicina, Universidad de la Republica, Uruguay 
 
13:00 – 14:30   Lunch 
 







Tuesday, May 22, 2012 (continued) 
 
 
15:30 – 19:00 Session VI: Oncology and therapeutic vaccines 
 Session Chairs:   
 John Aunins, Janis Biologics  
 Amine Kamen, National Research Council 
 
15:35 – 16:15 Keynote:  Oncolytic viruses as cancer therapies 
 Stephen Russell, Mayo Clinic, USA  
 
16:15 – 16:35 Vaccine potential of replicating oncolytic virus vectors 
 John C. Bell, Ottawa Hospital Research Institute, Canada 
  
16:35 – 17:05 The CMC challenges in developing an oncolytic immunotherapy 
 Colin Love, Amgen, USA 
 
17:05 – 17:30 Coffee break 
 
17:30 – 17:50 Development of novel cell-based immunotherapies 
 Madhusudan Peshwa, Maxcyte, USA  
 
17:50 – 18:10 Process development for a peptide conjugated qbeta virus-like particle 
 (VLP) vaccine 
 Jennifer Thorn, Pfizer, USA 
 
18:10 – 18:30 Chimpanzee ad vector technology platform for prophylactic and therapeutic 
genetic vaccine applications 
 Stefano Colloca, Okairos, Italy 
 
18:30 – 18:50 Cervical cancer immunotherapy:  Induction of HPV specific CTLs in  human 
volunteers after VGX-3100 immunization 
 Niranjan Y. Sardesai, Ph.D., Inovio Pharmaceuticals, Inc., USA  
 
19:00 – 20:30 Dinner 
 




Wednesday, May 23, 2012 
 
 
07:00 – 08:30 Breakfast 
 
08:30 – 12:40 Session VII: Bioprocess development and analytical tools  
 Session Chairs:   
 Luis Maranga, Novartis Vaccines & Diagnostics (NV&D) 
 Laura Palomares, UNAM, Mexico  
  
 Sponsored by BIA Separations 
 
8:30 – 09:00 Microbial fermentation:  New tools to speed-up vaccine antigen development 
 and increase process knowledge  
 Catherine Jourdat, Sanofi Pasteur, France  
 
09:00 – 09:30 Bacterial expression of a VLP Sub-unit for rapid and cheap influenza 
 vaccination  
 Anton Middelberg, University of Queensland, Australia  
 
09:30 – 10:00 High cell density cultivations for influenza virus production  
 Yvonne Genzel, Max Planck Institute for Dynamics of Complex Technical Systems, 
 Germany  
 
10:00 – 10:20 RMCE-based SF9 cell factory for production of multimeric VLPs  
 Ana P. Teixeira, ITQB-UNL/IBET, Portugal 
 
10:20 – 10:50 Coffee break 
 
10:50 – 11:20 Systematic characterization of adventitious agent testing for biological 
 medicinal products  
 Rebecca Sheets, NIH, National Institute of Allergy & Infectious Diseases, USA 
 
11:20 – 11:50 Automation and multiplexing of immunoassays: Improving precision and 
 throughput 
 Ilia Tikhonov, PPD, USA  
 
11:50 – 12:10 Developing a suite of analytics to support process development for the 
 manufacture of polysaccharides  
 Aaron Noyes, University College London, UK  
 
12:10 – 12:40 Prediction of serum bactericidal and opsonophagocytosis using a high-
 throughput flow cytometric antibody-mediated complement binding assay   
 for Neisseria Meningitidis  
 Andrew Gorringe, Health Protection Agency, UK  
 
12:40 – 14:00 Lunch  
 
14:00 – 15:00 ad hoc sessions 
 
15:00 – 16:30 Session VIII:  Biodefense, pandemic & emerging disease vaccines: (Part 1)  
 Session Chairs:  
 Barry Buckland, University College London 
 Phil Gomez, PriceWaterhouseCoopers 
 
15:00 – 15:30 Development of vaccines for Ebolavirus 







Wednesday, May 23, 2012 (continued) 
 
 
15:30 – 16:00 BARDA vaccine program   
 Bob Huebner, BARDA, USA  
 
16:00 – 16:30 Sabin-IPV process development and optimization for cost-price reduction  
 and technology transfer purposes  
 Wilfried A.M. Bakker, National Institute for Public Health and the Environment 
 (RIVM), Netherlands 
 




Thursday, May 24, 2012 
 
 
07:00 – 08:30 Breakfast 
 
08:30 – 13:00 Session IX: New technologies and approaches  
 Session Chairs:  
 Mike Hoare, University College London 
 Herve Pinton, Sanofi Pasteur 
  
 Sponsored by Sartorius Stedim Biotech  
 
08:30 – 09:00 Bacterium-like particles as delivery vehicles for multimeric antigens 
 Kees Leenhouts, Mucosis B.V., Netherlands  
 
09:00 – 09:20 Production of bacterial outer membrane vesicles for antigen delivery  
 Bas van de Waterbeemd, RIVM/Vaccinology/Process Development, Netherlands 
 
09:20 – 09:50 Mutiply activated VLP influenza vaccines  
 James Swartz, Stanford University, USA 
 
09:50 – 10:10 Endotoxin-free E. Coli hosts for vaccine discovery and production  
 David Bramhill, Research Corporation Technologies, USA 
 
10:10 – 10:30 Micro-scale vaccine development – A tools set for success  
 Tarit K. Mukhopadhyay, University College London, UK  
 
10:30 – 11:00 Coffee break 
 
11:00 – 11:30 Novel glycoconjugate vaccines based on rationally designed synthetic 
 carbohydrate antigens  
 A. Stewart Campbell, Ancora Pharmaceuticals, Inc., USA 
 
11:30 – 12:00 Automated single-use centrifugation and cell-washing solution for vaccine
 manufacturing  
 Sunil Mehta, kSep Systems, LLC 
 
12:00 – 12:30 Utilizing ‘omics tools to investigate the impact of process changes on 
 product quality in cell culture-based influenza vaccine production 
 Erdmann Rapp, Max Planck Institute for Dynamics of Complex Technical Systems 
 
12:30 – 13:00 Monolithic columns for purification and in-process control of viruses and 
 virus-like particles  
 Lidija Urbas, BIA Separations, Slovenia 
  
13:00 – 14:00 Lunch 
 
14:00 – 15:00 ad hoc sessions, free time 
 
15:00 – 17:20 Session VIII:  Biodefense, pandemic & emerging disease vaccines: (Part 2) 
 
15:00 – 15:25 Plant-made influenza virus-like particles: For pandemic and beyond 
 Nathalie Charland, Medicago, Canada  
 
15:25 – 15:50 Flunisyn: Advanced development of a synthetic universal influenza t-cell
 vaccine 
 Campbell Bunce, PhD, Immune Targeting Systems (ITS) Ltd., UK 
 
 
Thursday, May 24, 2012 (continued) 
 
 
15:50 – 16:15 Purification of cell-based influenza H5N1 viruses by liquid chromatography 
 technologies  
 Alan Yung-Chih Hu, National Institute of Infectious Diseases and Vaccinology, NHRI, 
 Taiwan 
 
16:15 – 16:40 Viral sensitizer technology improves yield of modified vaccinia ankara from 
 available cell substrates  
 Fabrice Le Boeuf, Ottawa Hospital Research Institute, Center for Innovative Cancer 
 Therapeutics, Canada 
 
16:40 – 17:05 Suspension vero cells (SVERO) for poliovirus production:  Effect of culture 
 passage on growth kinetics and productivity  
 Guillermina Forno, Universidad Nacional del Litoral, Argentina 
 
17:05 – 17:35 Coffee break 
 
17:35 – 18:05 Keynote  
 Monitoring immune response on a cell by cell basis 
 Christopher Love, MIT, USA    
 




Friday, May 25, 2012 
 
 
07:00 – 10:30 Breakfast and departures 





1.  Development of multivalent protein capsular matrix vaccine (PCMV) technology 
Kevin Killeen, Matrivax R&D Corporation, USA 
 
2.  Development and scale-up of a high yield transient transfection platform for the 
production of a Chikungunya virus-like particle vaccine 
Joshua Merritt, National Institutes of Health, USA 
 
3.  Visualization of domain structure and flexibility of proteins and protein complexes using 
TEM 
Bridget Carragher, NanoImaging Services, Inc., USA 
 
4.  Impact of the ligand density on adenovirus serotype 5 purification using membrane 
chromatography. 
Piergiuseppe Nestola, IBET/ITQB-UNL, Portugal 
 
5.  Towards a better understanding of on-line multifrequency permittivity measurements of 
adherent Vero cell cultures in perfused processes 
A. El Wajgali, CNRS-Université de Lorraine, France 
 
6.  Universal influenza virus vaccine based on the conserved stalk domain of the 
hemagglutinin 
Florian Krammer, Mount Sinai School of Medicine, USA 
 
7.  Rapid cell line selection and process development using high-throughput technologies, 
design of experiments (DOE) and quality by design 
Tiffany D Rau, Rau and Associates, USA 
 
8.  New approaches in intensification and optimization of integrated malaria vaccine 
production with Pichia pastoris 
Jens Fricke, HAW-Hamburg University of Applied Sciences, Germany 
 
9.  Evaluation of critical process parameters and operation range for successful scale up and 
robust manufacturing of reolysin® 
Amine Kamen, National Reserach Council, Canada 
 
10.  Tetravalent dengue vaccine produced at Insituto Butantan 
Vanessa Takinami, Instituto Butantan, Brazil 
 
11.  Pentavalent rotavirus vaccine - stability study 




12.  Analysis and optimization of a sequential malaria vaccine production process with in-situ 
product removal (ISPR) 
Sanja Martens, University of Applied Sciences Hamburg, Germany 
 
13.  Dendritic cell-targeting nanoparticle-based pulmonary vaccines for inducing potent cellular 
immune responses 
Jeffrey A. Hubbell, Ecole Polytechnique Federale de Lausanne (EPFL), Switzerland 
 
14.  Engineering of  Escherichia coli strains specifically for plasmid biopharmaceutical 
production 
Geisa A. L. Gonçalves, Instituto Superior Técnico (IST), Portugal 
 
15.  Semliki forest virus expressing rabies virus glycoprotein: Synthesis and protection studies. 
Carlos A Pereira, Instituto Butantan, Brazil 
 
16.  Affordable inactivated polio vaccine using modular facilities and disposable technology – 
potential for local sustainable production of vaccine in low- and middle-income countries 
A.G.Lopes, LLB Global Health Solutions Ltd., United Kingdom 
 
17.  Influenza production kinetics in HEK293 cell cultures 
Amine Kamen, National Research Council of Canada - Vaccine Program, Canada 
 
18.  Target cells for antibodies detection in rabies vaccine control 
Diego Fontana, Universidad Nacional del Litoral, Argentina 
 
19.  A strategy for scale-up of adherent Vero cells using cytodextm microcarriers and WAVE 
bioreactortm systems 
Ann-Christin Magnusson, GE Healthcare, Sweden 
 
20.  Live attenuated influenza virus production in batch high cell density cultivation of 
suspension AGE1.CR.pix cells 
Verena Lohr, Max-Planck-Institute for Dynamics of Complex Technical Systems, Germany 
 
21.  Quantification of GFP-labeled virus-like particles by spectrofluorometry 
Francesc Godia, Universitat Autònoma de Barcelona, Spain 
 
22.  Development of serum-free medium supplemented with non-animal derived components 
for production of virus-like particles in HEK 293 cell cultures 
Francesc Godia, Universitat Autònoma de Barcelona, Spain 
 
23.  Investigation into proteolytic clipping of product from manufacturing consistency lots 
Michael Kosinski, Merck & Co., Inc., USA 
 
24.  Production of safe transgene delivery vectors- minicircles 




25.  An animal component free medium that promotes the growth of various animal cell lines 
for the production of viral vaccines 
Héla Kallel, Institut Pasteur de Tunis, Tunisia 
 
26.  Study of dengue virus replication in vero cells 
Vanessa Harumi Takinami, Instituto Butantan, Brazil 
 
27.  Development a vectored vaccine against Hepatitis E virus 
Héla Kallel, Institut Pasteur  de Tunis, Tunisia 
 
28.  Subunit Leptospiral immunoglobulin-like (Lig) protein vaccine protects against lethal 
challenge in the hamster model of leptospirosis 
Marco Alberto Medeiros, Oswaldo Cruz Foundation (FIOCRUZ), Brazil 
 
29.  Improvements on peste des petits ruminants vaccine stability during production and 
storage 
Paula Alves, IBET/ITQB-UNL, Portugal 
 
30.  Production of adenovirus vectors in human amniocyte-derived cells 
Paula Alves, IBET/ITQB-UNL, Portugal 
 
31.  Development of a membrane adsorber-based capture step for the purification of yellow 
fever virus 
Tania P. Pato, Oswaldo Cruz Foundation (FIOCRUZ), Brazil 
 
32.  Process development and technology transfer of a high yield fermentation process for 
cgmp production of plasmid DNA vaccines 
Aaron E. Carnes, Nature Technology Corporation, USA 
 
33.  Sensitive methods for evaluation of antibodies for host cell protein analysis and screening 
of impurities through out a vaccine process 
Christine Sund-Lundström, GE Healthcare Biosciences AB, Sweden 
 
34.  Use of a hydrocyclone as cell retention device in a perfusion process with BHK-21 Cells 
infected with bovine rabies virus 
Ricardo Medronho, Federal University of Rio de Janeiro, Brazil 
 
35.  Optimization of TRT virus production in bioreactor 
Lídia Garcia, Pfizer Olot S.L.U, Spain 
 
36.  Adenovirus based vaccine formulations: A 5.5-year stability storage study 
Marcos F. Q. Sousa, Universidade Nova de Lisboa, Portugal 
 
37.  In vivo active delivery of antigens to splenic dendritic cells by engineered bio-nanocapsules, 
hepatitis B virus surface antigen L protein particles 
Hidenori Matsuo, Nagoya University, Japan 
 
 
38.  Influenza antigen design on virus-like particles 
Linda Lua, The University of Queensland, Australia 
 
39.  Development of monovalent oral poliovirus vaccines types 1, 2, and 3 
Marisela Morales Moreno, Laboratorios de Biologicos y Reactivos de Mexico S.A. de C.V. 
(BIRMEX), Mexico 
 
40.  Linear scalability for viral entities production in icellis™ disposable fixed-bed bioreactor 
from bench-scale to industrial scale 
Jean-Christophe Drugmand, ATMI LifeSciences, Belgium 
 
41.  Toolbox for non-intrusive structural and functional analysis of recombinant VLP based 
vaccines: A case study with hepatitis B vaccine 
Clinton  Potter, NanoImaging Services, Inc., USA 
 
42.  Structural tailoring of HEV capsid protein for gaining insights into vaccine design 
Shaowei Li, Xiamen University, China 
 
43.  Vaccine candidate process verification and performance qualification 
Jennifer Haas, Merck & Co., Inc., USA 
 
44.  Three VP6 formats: Nanotubes, virus-like particles and VP6 trimers protected mice against 
rotavirus infection 
Ana Ruth Pastor, Instituto de Biotecnología-Universidad Nacional Autónoma de México, 
Mexico 
 
45.  N-glycosylation determines the stability and immunogenicity of recombinant influenza 
hemagglutinin 
Laura A. Palomares, Instituto de Biotecnología. Universidad Nacional Autónoma de México, 
Mexico 
 
46.  Use of yeast extracts containing rotavirus-like particles and soluble rotavirus proteins as a 
low-cost veterinary vaccine 
William A. Rodríguez-Limas, Instituto de Biotecnología, Universidad Nacional Autónoma de 
México, Mexico 
 
47.  Pre-treatment of Japanese encephalitis virus with formaldehyde and glycine improves 
recovery from flow-through ion-exchange chromatography purification 
Michael Hughson, University College London, United Kingdom 
 
48.  Control and analysis of quaternary complexity in virus-like particle assembly 
Yap Pang Chuan, The University of Queensland, Australia 
 
49.  Development of cancer vaccine based on her-1 extracellular domain 
Adolfo Castillo, Center of Molecular Immunology, Cuba 
 
50.  Characterization of monolithic chromatographic support for phage purification 
Lidija Urbas, BIA Separations, Slovenia 
51.  Integration of monolithic analytical columns into the biopharmaceutical manufacturing 
process to enable fast and real-time HPLC analytical assay both up- and downstream 
Lidija Urbas, BIA Separations, Slovenia 
 
52.  Different strategies of pDNA purification processes on methacrylate monolithic columns 
Daniela Marc, BIA Separations, Slovenia 
 
53.  Characterization and immunogenicity of Chikungunya virus-like particle (CHIKV VLP) based 
vaccine 
Richard Schwartz, National Institutes of Health, USA 
 
 
  
